SoFi CEO enters prepaid forward contract on 1.5 million shares
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics company, has completed a share buyback transaction, repurchasing 992,762 of its ordinary shares at a price of 21.5 pence per share. The transaction took place on Thursday, with the shares to be held in treasury.
This buyback has adjusted the total issued share capital of the company to 454,930,564 ordinary shares, each with one voting right. After accounting for the treasury shares, the total number of voting rights in the company stands at 449,460,790. These figures are relevant for shareholders who need to disclose changes in their shareholding as per the Financial Conduct Authority’s rules.
Additionally, as part of the share repurchase, EKF acquired shares from investment entities managed by Harwood. Notably, 292,762 shares were bought from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, with the purpose of maintaining the aggregate indirect beneficial interest of Mr. Christopher Mills, a Non-Executive Director of EKF, below the 30% threshold of total voting rights post-repurchase.
Following the transaction, Mr. Mills’ indirect interest in EKF Diagnostics totals 132,541,418 ordinary shares. The company has made it clear that this announcement contains inside information pursuant to market abuse regulations.
EKF Diagnostics operates globally, with headquarters in Penarth, near Cardiff, and manufacturing facilities in the United States and Germany. The company specializes in point-of-care analyzers in hematology and diabetes, as well as life sciences services, including the manufacturing of enzymes and custom products for diagnostic, food, and industrial applications.
This news is based on a press release statement from EKF Diagnostics Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.